Literature DB >> 16963480

Circulating antibodies to nephrin in patients with type 1 diabetes.

Petri Aaltonen1, Johanna Rinta-Valkama, Anu Pätäri, Päivi Tossavainen, Tuula Palmén, Petri Kulmala, Mikael Knip, Harry Holthöfer.   

Abstract

BACKGROUND: Patients with type 1 diabetes typically develop autoantibodies to antigens of the pancreatic islet cells including insulin, glutamic acid decarboxylase and the protein tyrosine phosphatase-related islet antigen 2 protein. Nephrin is a protein shared by the kidney glomeruli, pancreatic beta-cells and islet microendothelia. Since circulating antibodies to nephrin have been shown to cause proteinuria, we wanted to test whether such autoantibodies can be detected in diabetic patients.
METHODS: We developed a radioimmunoprecipitation assay and analysed samples in a follow-up series of 66 patients with type 1 diabetes.
RESULTS: A total of 24% of the patients tested positive for nephrin autoantibodies at diagnosis, whereas 23, 14 and 18% had these antibodies at 2, 5 and 10 years, respectively. During the follow-up at 16-19 years after diagnosis, 14 patients had signs of renal injury and 29% of them tested positive for nephrin autoantibodies in at least one sample.
CONCLUSIONS: We conclude that a subset of patients with type 1 diabetes present with circulating autoantibodies to nephrin. However, the present data do not allow conclusions of a causative role for these antibodies in the pathogenesis of proteinuria in diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16963480     DOI: 10.1093/ndt/gfl486

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  3 in total

1.  Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution.

Authors:  Martin Bitzan; Jodie D Ouahed; Preetha Krishnamoorthy; Chantal Bernard
Journal:  Pediatr Nephrol       Date:  2008-03-20       Impact factor: 3.714

Review 2.  Molecular Mechanisms of Proteinuria in Minimal Change Disease.

Authors:  Shrey Purohit; Federica Piani; Flor A Ordoñez; Carmen de Lucas-Collantes; Colin Bauer; Gabriel Cara-Fuentes
Journal:  Front Med (Lausanne)       Date:  2021-12-23

3.  Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes.

Authors:  Oscar Rubio-Cabezas; Jayne A L Minton; Richard Caswell; Julian P Shield; Dorothee Deiss; Zdenek Sumnik; Amely Cayssials; Mathias Herr; Anja Loew; Vaughan Lewis; Sian Ellard; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2008-10-17       Impact factor: 17.152

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.